Related by context. All words. (Click for frequent words.) 86 Secondary endpoints included 76 Secondary endpoints 74 Primary endpoints 73 demonstrated clinically meaningful 71 progression TTP 69 adjuvant GIST 69 Secondary efficacy endpoints 68 ADCS CGIC 67 tumor progression TTP 67 glycosylated hemoglobin levels 66 morphometric vertebral fractures 66 WOMAC pain 66 pharmacodynamic PD 66 desvenlafaxine succinate 66 prednisone prednisolone plus 66 Scale EDSS 66 glycosylated hemoglobin HbA1c 66 CRp 65 evaluable 65 ratio ICER 65 Montgomery Asberg Depression 65 postintervention 65 Median progression 65 Tasigna prolongs 65 prespecified secondary 65 CCyR 65 prospectively defined 65 prospectively stratified 65 relapsed MCL 65 CR CRu 65 secondary endpoint 65 secondary efficacy endpoint 65 % Confidence Interval 64 pharmacokinetics PK 64 PCWP 64 reactogenicity 64 serum urate 64 -#.# log# copies mL 64 Crohn Disease Activity 64 patients evaluable 64 8mg/kg 64 ispinesib administered 64 Free Survival PFS 64 postoperative AF 64 intravascular hemolysis 64 endoscopic remission 64 RECIST Response Evaluation Criteria 64 #.#/#.# mmHg [001] 64 symptom exacerbation 64 Kaplan Meier estimates 64 nasal symptom 64 corticosteroid dose 64 recurrent venous thromboembolism 64 CIMZIA TM certolizumab pegol 64 cEVR 64 microbiologically evaluable 64 Pharmacodynamic 64 serum phosphorous 64 bortezomib refractory 64 urinary N telopeptide 64 haematologic 63 clinicopathological features 63 corrected QT interval 63 certolizumab 63 Pharmacokinetic parameters 63 DAS# CRP 63 #mg QD [002] 63 relapsed MM 63 activated partial thromboplastin 63 neurologic progression 63 Flu Cy 63 confirmed CCyR 63 hemodynamic measurements 63 Index CDAI 63 DAS# remission 63 serologically active patients 63 annualized relapse 63 achieved ACR# 63 Severity MSCS score 63 RECIST criteria 63 intact parathyroid hormone 63 ACTEMRA TM 63 posttreatment 63 cytogenetic response 63 hemoglobin A1c HbA1c 63 abdominal pain abdominal discomfort 63 symptomatic VTE 63 calculated creatinine clearance 63 demonstrated statistically significant 63 ADCS ADL 63 bronchial hyperresponsiveness 63 HAQ DI 63 Brief Psychiatric 63 microbiological eradication 63 surrogate endpoint 63 radiotherapy RT 63 biochemical relapse 63 intermittent dosing 63 Kaplan Meier estimate 63 HDRS 63 ADAS Cog 63 Response Evaluation Criteria 63 #mg/day [001] 62 4mg/kg 62 confidence interval CI 62 p = NS 62 #mg/day [002] 62 galiximab 62 Zometa hazard 62 demonstrated antitumor activity 62 erection hardness 62 CR nPR 62 ATACAND 62 mg QD 62 Fasting plasma glucose 62 partial remissions 62 LDL triglycerides 62 achieved statistical significance 62 p = #.# [004] 62 inhaled iloprost 62 SGRQ 62 clinically meaningful improvements 62 hematological parameters 62 Solid Tumors criteria 62 statistically significant improvement 62 plasma leptin 62 pulmonary exacerbations 62 response CCyR 62 clinically meaningful improvement 62 HER2 expression 62 BEXXAR Therapeutic Regimen 62 tipranavir r 62 viral kinetics 62 venous thromboembolic disease 62 CIMZIA TM 62 PASI scores 62 Viral load 62 CIMZIA ™ 62 pharmacodynamics PD 62 HOMA IR 62 torsemide ER 62 tumor histology 62 SSRI SNRI 62 intratumoral 62 lispro 62 plus prednisone 62 limiting toxicity DLT 62 % CI #.#-#.# [003] 62 nicardipine 62 severe oral mucositis 62 HF hospitalization 62 Erythropoietic therapies may 62 aspartate aminotransferase AST 62 abacavir lamivudine 62 recovery CRp 61 biochemical recurrence 61 NIH CPSI 61 epoetin alpha 61 mcg QD 61 melphalan prednisone 61 P = .# 61 estimated glomerular filtration 61 headache nasopharyngitis 61 achieved CCyR 61 fractional shortening 61 remission CR 61 Cystic Fibrosis Questionnaire Revised 61 FOLFIRI alone 61 serum cortisol 61 FUSILEV enhances 61 Known hypersensitivity 61 placebo p = 61 PSA nadir 61 Psoriasis Area 61 attain statistical significance 61 pharmacokinetic parameters 61 oxycodone CR 61 prespecified 61 peginterferon alfa 2a #KD 61 adjuvant cisplatin 61 hyperphenylalaninemia HPA due 61 pharmacokinetic PK 61 overt hepatic encephalopathy HE 61 #mg/m# [002] 61 achieved sustained virologic 61 naïve HCV 61 EBMT criteria 61 serum HBV DNA 61 plus prednisone prednisolone 61 reinfarction 61 deep venous thromboses 61 achieve sustained virologic 61 elevated ALT 61 YMRS 61 fasting plasma glucose FPG 61 AST ALT 61 primary efficacy endpoint 61 Visual Analogue Scale VAS 61 hemostatic efficacy 61 permanently discontinue Vectibix 61 intima media thickness 61 #q# deletion syndrome 61 p = .# [002] 61 recurrent ischemia 61 clinically meaningful reductions 61 APTIVUS r 61 glomerular filtration 61 Events MACE 61 preintervention 61 Symptom severity 61 free survival PFS 61 colorectal adenoma 61 systemic mastocytosis SM 61 CDAI 61 brachial artery flow 61 achieved sustained virological 61 mean ± SEM 61 ACR Pedi 61 natriuresis 61 Main Outcome Measures 61 response pCR 61 thrombocytopenic 61 highest tertile 61 HRQoL 61 mild hepatic impairment 61 oral prednisolone 61 pharmacodynamic effects 61 fructosamine 61 Folfox 61 mg/m2 cohort 61 complete cytogenetic 61 sleep onset WASO 61 posttest 61 + PH# 61 sUA 61 pharmacodynamic parameters 61 secondary endpoints 61 linaclotide treated 61 HBeAg negative patients 61 #mg BID [003] 61 EDARBI 60 mg TID 60 elevated transaminases 60 International Prostate Symptom 60 exploratory endpoints 60 repeat paracentesis 60 secondary efficacy endpoints 60 Mean Symptom Complex 60 aPTT 60 echocardiographic parameters 60 liver histology 60 cisplatin gemcitabine 60 XIENCE V demonstrated 60 leukocyte count 60 adenoma recurrence 60 serum aminotransferase levels 60 recurrent glioblastoma multiforme 60 HbA1C levels 60 preoperative PSA 60 nonfatal myocardial infarction 60 CYP#A# substrate 60 hip BMD 60 ADAS cog 60 histologic 60 mesalamine granules 60 Severity Index PASI 60 plasma cortisol 60 EGFR expressing mCRC 60 Zemplar Capsules 60 plasma uric acid 60 mediated dilation 60 lymphocytosis 60 catheter occlusion 60 Insulin sensitivity 60 ACR# ACR# 60 achieved PASI 60 multivariate Cox 60 chlorambucil 60 plus methotrexate 60 histologic subtype 60 moderate renal impairment 60 pain palliation 60 posttransplant 60 Pharmacokinetics PK 60 recombinant PSMA vaccine 60 plus COPEGUS 60 VELCADE melphalan 60 ARCALYST ® 60 oral rivaroxaban 60 pharmacodynamic markers 60 hsCRP levels 60 HBeAg positive patients 60 Qmax 60 serum bicarbonate 60 FEV1 forced expiratory 60 PANSS 60 antiangiogenic therapy 60 neutropenic sepsis 60 #mg BID [002] 60 p = #.# [002] 60 Score DAS 60 GERD symptom 60 UPDRS Part III 60 hemagglutination inhibition HAI 60 erythrocyte sedimentation rate 60 symptomatic intracranial hemorrhage 60 pCR 60 REMINYL ® 60 imatinib therapy 60 Montgomery Åsberg Depression 60 -#.# mg dL [002] 60 metastatic GIST 60 Scale cognitive subscale 60 pharmacokinetic PK profile 60 CYP#D# inhibitor 60 aspartate aminotransferase 60 dose cohort 60 6MWD 60 evaluable patients 60 left ventricular diastolic 60 moderate hepatic impairment 60 postdose 60 Persistent Sleep 60 LANTUS R 60 alanine aminotransferase 60 BENICAR HCT 60 indicates cardio circulatory 60 UPDRS scores 60 atazanavir ritonavir 60 hematologic parameters 60 Telintra 60 albumin excretion rate 60 QTc intervals 60 confidence interval #.#-#.# 60 intravenous bolus 60 subjective sleepiness 60 ascending dose 60 estramustine 60 pulmonary capillary wedge 60 spontaneous bowel movements 60 TURBT 60 clevidipine 60 Lupuzor ™ 60 urate lowering 60 sustained virological response 60 IRLS 60 viral tropism 60 Solid Tumors RECIST 60 EORTC QLQ C# 60 metabolic parameters 60 crizotinib PF # 60 FluCAM arm 60 Insulin PH# 60 CINQUIL 60 severe exacerbations 60 prospective multicentre 60 glycated hemoglobin levels 60 methacholine challenge 60 antiretroviral naive 60 locoregional recurrence 59 mg ustekinumab 59 #mg/m# [001] 59 virologic responses 59 plus dexamethasone 59 lipid parameters 59 mg qd 59 periprocedural 59 β blocker 59 Major Adverse Cardiac 59 meta regression 59 CFQ R 59 -#.# mg dL [001] 59 ELACYT 59 ug kg 59 TLUS 59 GnRH agonist 59 tolterodine ER 59 XIENCE V PROMUS Stent 59 IIIa inhibitor 59 MCyR 59 pharmacokinetic profiles 59 phonophobia 59 CI -#.# 59 HBeAg seroconversion 59 Alzheimer Disease Assessment 59 Sustained virologic response 59 serum antibody 59 IBDQ 59 Main Outcome Measure 59 QTcF 59 plasma triglycerides 59 antiretroviral naïve 59 timepoints 59 Platelet counts 59 docetaxel pretreated 59 CK # plasma concentrations 59 Neuropsychiatric Inventory NPI 59 velafermin 59 non splenectomized 59 DLQI 59 pretransplant 59 genotypic resistance 59 TAXUS Express Stent 59 myocardial infarction ventricular fibrillation 59 electrophysiologic 59 EGFr expressing metastatic colorectal 59 mucosal healing 59 oral levofloxacin 59 MGN# 59 Y BOCS 59 novel VDA molecule 59 Kaplan Meier analysis 59 REYATAZ r arm 59 N telopeptide 59 mg kg dose 59 irinotecan cisplatin 59 brand ciclesonide HFA 59 Pharmacokinetic 59 TAXUS p value 59 perinatal morbidity 59 serum phosphate 59 nighttime awakenings 59 pharmacodynamic 59 coinfected patients 59 PEG IFN 59 tipranavir ritonavir 59 triglyceride concentrations 59 splenectomized patients 59 mitoxantrone plus 59 mg kg Hematide 59 alfuzosin 59 oocytes retrieved 59 CANCIDAS 59 urine albumin 59 Score DAS# 59 Triapine R 59 endometrial thickness 59 Rating Scale MADRS 59 ischemia driven 59 Kaplan Meier 59 serum ALT 59 linear pharmacokinetics 59 locoregional disease 59 doxorubicin docetaxel 59 undetectable HBV DNA 59 lowest tertile 59 saline placebo 59 AUC0 59 oblimersen 59 ug dose 59 antiarrhythmic drug 59 CIMZIA R 59 = #.#-#.# 59 mg kg BID 59 p = #.# [003] 59 tissue oxygenation 59 serum IGF 59 shortens systolic ejection 59 nasopharyngitis headache 59 pegylated alpha interferon 59 Cmax 59 Hamilton Anxiety Scale 59 BENICAR 59 oral antidiabetic medication 59 tumor lysis syndrome 59 tolerability profiles 59 dose dependently 59 nonfatal myocardial infarction MI 59 â ‰ ¥ 59 RRM1 59 Target Lesion Revascularization TLR 59 bioavailable testosterone 59 quetiapine XR 59 binary restenosis 59 Unified Parkinson Disease 59 % CI #.#-#.# [008] 59 acromegalic patients 59 serum concentrations 59 univariate 59 SVR# 59 NPH insulin 59 pegylated interferon alfa 2b 59 CI #.#-#.# [002] 59 pharmacokinetic characteristics 59 rituximab refractory 59 Aptivus ® 59 cytogenic 59 histological subtype 59 antibody titer 59 stent binary restenosis 59 EDEMA3 trial 59 % CI #.#-#.# [001] 59 plus octreotide LAR 59 #.#mg/dL 59 postoperative inflammation 59 intracoronary 59 Score TOS 59 % CI #.#-#.# [005] 59 TIMP 1 59 Q#IR 59 alanine aminotransferase ALT 59 virological response 59 mg p = 59 irbesartan 59 plasma pharmacokinetics 59 liver transaminases 59 neutropenia dehydration dyspnea 59 neurocognitive function 58 dosing cohort 58 Score IPSS 58 methotrexate monotherapy 58 unfractionated heparin UFH 58 flow mediated dilation 58 HAMD 58 % CI #.#-#.# [007] 58 pyrimidine nucleoside analog 58 μg kg 58 Seattle Angina Questionnaire 58 hours postdose 58 Kaplan Meier survival 58 IU ml 58 composite endpoint 58 PSADT 58 NYHA functional class 58 hemoglobin Hb 58 salmeterol fluticasone 58 Acetate Rectal Suppositories 58 lymphopenia 58 lactate dehydrogenase 58 rFSH 58 overt nephropathy 58 systolic function 58 achieving hemostasis 58 Change PGIC 58 spirometric 58 NIHSS 58 MADRS score 58 PROCTOCORT ® Suppository Hydrocortisone 58 #μg [002] 58 ischemic cardiovascular 58 vitreous floaters 58 fluticasone salmeterol 58 perioperatively 58 lopinavir r arm 58 BMI percentiles 58 glycated hemoglobin HbA1c 58 STRIDE PD 58 RoACTEMRA 58 inhaled budesonide 58 PLX STROKE targeting 58 QIDS SR 58 diarrhea dyspepsia 58 IFN α 58 mcg kg 58 gemcitabine Gemzar ® 58 LDB CPR 58 autoantibody levels 58 NATRECOR R 58 CK # plasma 58 UPDRS motor 58 selective modulator 58 NATRECOR ® 58 mg BID 58 malignancy HCM 58 NMIBC 58 INTEGRILIN R eptifibatide Injection 58 affective psychosis 58 maximal tolerated 58 MADRS 58 salmeterol fluticasone propionate 58 F FDG PET 58 primary percutaneous coronary 58 PSA kinetics 58 androgen suppression 58 oral diclofenac 58 GH deficiency 58 laboratory abnormalities 58 treatment naive genotype 58 IMPACT DCM 58 teriflunomide 58 angiographic restenosis 58 Raptiva r 58 ULORIC 58 NNT = 58 specific antigen PSA 58 transdermal estradiol 58 HIV HCV coinfected 58 ≥ 58 hypoglycemic events 58 plasma creatinine 58 -#.# ± [002] 58 neutropaenia 58 Prostate specific antigen 58 esophageal carcinoma 58 hMG 58 seroprotection 58 lumbar spine BMD 58 hepatic enzyme 58 Scale PANSS 58 #beta estradiol 58 plasma lipids 58 LEXIVA r 58 pyrexia mucositis sepsis febrile 58 CDAI score 58 icatibant 58 plus ribavirin 58 microvessel density 58 serum lipid 58 Rate ORR 58 unresectable HCC 58 serum potassium 58 disease progression TTP 58 alicaforsen enema 58 HbA1C 58 KRAS mutations occur 58 TDF FTC 58 paclitaxel poliglumex 58 mmHg diastolic 58 comparator arm 58 hepatic insufficiency 58 mm Hg diastolic 58 Cardiorespiratory fitness 58 Androxal TM 58 CD4 CD8 58 glycoprotein IIb IIIa inhibitor 58 LAB CGRP 58 venlafaxine XR 58 acoustic startle 58 papillary renal cell carcinoma 58 #μg [001] 58 erythropoietic 58 RECIST 58 placebo p 58 CSBM 58 doxorubicin cyclophosphamide 58 clodronate 58 Prognostic significance 58 reduce serum phosphate 58 QRS duration 58 nucleoside naive 58 ACR# response 58 Health Assessment Questionnaire 58 thrombin inhibiting aptamer 58 FOLPI 58 carotid artery intima media 58 systemic corticosteroid 58 somatostatin analog 58 myocardial reperfusion 58 peak VO2 58 Cardiopulmonary bypass 58 nausea photophobia 58 mg/m2/day 58 vasomotor 58 carotid IMT 58 methemoglobin SpMet 58 Hematologic toxicity 58 complete cytogenetic response 58 nodular partial response 58 mild renal insufficiency 58 bone marrow reticulin 58 Targretin capsules 58 Skin sterol 58 Pfizer respectfully disagrees 58 serum parathyroid hormone 58 QTc prolongation 58 mg/m2 dose 58 indiplon capsules 58 Hb A1C 58 multivariable Cox 58 Partial Response 58 ancrod 58 CYP#A# CYP#D# 58 QTc 58 ionotropic 58 pretreatment serum 58 tapentadol ER 58 vidofludimus 58 IELT 58 Hazard Ratio HR 58 hemoglobin A1C HbA1C 58 alfa 2a 58 statistically significant p = 58 Kinoid 58 primary endpoint 58 serum leptin 58 timepoint 58 tryptase 58 R Saizen R 58 postmenopausal osteoporotic women 58 interleukin IL -6 58 HAM D# 58 hemodynamic variables 58 corticosteroids immunoglobulins 58 #.#mmHg 58 Mg Uk 58 R# #mg BID 58 5 Fluorouracil 58 acute mania 58 PANSS scores 58 SCr 58 Expanded Disability Status 58 utmost importance Breithaupt 58 Efficacy endpoints 58 mg BID dose 58 forodesine 58 AERx ® 58 lactate dehydrogenase LDH 58 AGGRASTAT ® tirofiban hydrochloride 58 Index CDAI score 58 hemodynamically stable 58 Perforomist TM formoterol fumarate 58 administering XIFAXAN 58 esophageal acid 58 myopathy rhabdomyolysis 58 Drug eluting stent 58 univariate analysis 58 balsalazide 58 efficacy tolerability 58 apolipoprotein B 58 BMI z 58 prospectively evaluated 58 retinal thickness 58 tamoxifen Nolvadex ® 58 CORE OM 58 HLA DR2 58 atherothrombotic events 58 HES CEL 58 hepatic insulin sensitivity 58 #dhTxB# 58 patients coinfected 58 hepatic function 58 interferon ribavirin 58 Natalizumab 58 fasting plasma 58 adjunctive placebo 58 death reinfarction 57 KRAS status 57 HbA 1c levels 57 moderately emetogenic 57 Cimzia TM 57 nadolol 57 urinary albumin excretion 57 Multivariate logistic regression 57 recurrent genital herpes 57 glucocorticoid induced 57 pegylated IFN 57 urinary cortisol 57 parasitological 57 tirofiban 57 interferon gamma 1b 57 highly emetogenic 57 Platinol ® cisplatin 57 intratympanic 57 cardiovascular hospitalizations 57 plus MTX 57 nadroparin 57 L PPDS 57 avosentan 57 thromboxane A2 57 intravenous cyclophosphamide 57 Index FSFI 57 pmol L 57 XIENCE V vs. 57 onset diabetes mellitus 57 COPD exacerbations 57 external genital lesions 57 VcMP 57 MACCE 57 calcineurin inhibitor 57 inotropic 57 baseline HbA1c 57 hepatic arterial 57 SGPT 57 Thrombotic thromboembolic complications 57 cystoscopic 57 oral ibandronate 57 n = 57 receiving XGEVA 57 nonfasting 57 TAXUS VI 57 coagulation abnormalities 57 mg RDEA# 57 q#h 57 preterm neonates 57 myelodysplastic myeloproliferative diseases 57 zonisamide SR 57 BPH symptom 57 Apgar scores 57 MoxDuo TM IR 57 intravesical 57 pulmonary exacerbation 57 r hGH 57 gout flares 57 infliximab monotherapy 57 serum prostate 57 chemoradiation therapy 57 hemodilution 57 CHOP chemotherapy 57 EDEMA4 trial 57 β blockers 57 TO AVOID PREGNANCY WHILE 57 neutrophil counts 57 partial thromboplastin 57 peg interferon 57 IOP lowering 57 x ULN 57 serum lipid levels 57 ITU algorithms PAMS 57 analgesic efficacy 57 Univariate analysis 57 locoregional 57 Perforomist Inhalation Solution 57 CC genotype 57 Global Impression CGI 57 achieving PASI 57 MAGE A3 ASCI 57 azilsartan medoxomil 57 Vidaza ® 57 otamixaban 57 intravenous iv 57 statistically significant p 57 plasma renin activity 57 AAG geldanamycin analog 57 CRMD# 57 plasma folate 57 coadministration 57 tumor regressions 57 3mg/kg 57 periodically reassessed 57 DAS# scores 57 % CI #.#-#.# [006] 57 CYP#D# genotype 57 trough FEV1 57 PEGPH# 57 low dose cytarabine 57 Negative Syndrome 57 cardiovascular thrombotic 57 Sanofi Pasteur Fluzone 57 nonfatal MI 57 Kaplan Meier method 57 systolic diastolic 57 postprandial insulin 57 culture supernatants 57 confidence intervals CIs 57 steroid refractory 57 serum PTH 57 Newly Diagnosed Multiple Myeloma 57 rosuvastatin #mg 57 ALT normalization 57 postoperative mortality 57 steroid dexamethasone 57 sensitivity specificity 57 locoregional control 57 Engerix B 57 GAMMAGARD 57 daily subcutaneous injections 57 metastatic pancreatic 57 mL/min/#.# m2 57 subcutaneous enoxaparin 57 creatinine ratio 57 symptomatic atrial fibrillation 57 antiandrogen 57 HRQOL 57 cardiac contractility 57 Fulvestrant 57 hypogonadal men 57 Serum creatinine 57 incidence ≥ 57 elevated creatinine 57 mCi kg 57 humanized interleukin 6 57 piperacillin tazobactam 57 receiving INTRON 57 EQ 5D 57 C telopeptide 57 KRAS mutant tumors 57 pegylated interferon peg IFN 57 nondiabetic patients 57 rhGH 57 elevated IOP 57 FOLFOX4 57 -#.# mm Hg 57 NSAID associated 57 p = 57 AUA Symptom Score 57 serum triglycerides 57 paraprotein 57 pT3 57 cells mcL 57 NovoSeven ® 57 ANCOVA 57 Mantel Haenszel 57 protein excretion 57 REGN# 57 myeloperoxidase 57 Aloxi injection 57 Virological 57 lispro alone 57 thetreatment 57 fraction LVEF 57 APPRAISE 57 GOUT 57 postprandial blood glucose 57 fasting insulin 57 lymphocyte count 57 cardiovascular morbidity 57 Tumor Response 57 recurrent malignant glioma 57 WOMAC TM 57 sonographically guided 57 anticholinergic agents 57 beclomethasone dipropionate 57 Amgen Neulasta R 57 ™ pralatrexate injection 57 ‰ ¥ 57 advanced hepatocellular carcinoma 57 receiving prophylactic anticoagulation 57 undetectable HCV RNA 57 CMV reactivation 57 containing abacavir 57 detectable HCV RNA 57 octreotide LAR 57 salivary flow 57 coronary revascularisation 57 hypomagnesemia 57 Cystatin C 57 KRAS mutation status 57 HBeAg 57 nonfatal stroke 57 undergoing percutaneous coronary 57 pegylated interferon alpha 57 serum clusterin levels 57 achieving sustained virologic 57 neutropenia thrombocytopenia 57 CYT# potent vascular disrupting 57 oral FTY# 57 splenectomized 57 Sensitivity specificity 57 EGFR mutation positive 57 pulse amplitude 57 postoperative morbidity 57 ribavirin RBV 57 platelet reactivity 57 Solid Tumours 57 CALGB # [002] 57 dose escalation phase 57 everolimus eluting stents 57 macroalbuminuria 57 mRCC 57 morbidity mortality 57 Doxil ® 57 dalteparin 57 Postoperative 57 oral methylnaltrexone 57 CD# upregulation 57 assessing T DM1 57 Clinically significant 57 Inventory BPI 57 EEG abnormalities 57 TAXUS Liberté stent 57 walk distance 6MWD 57 QD dosing 57 ® lenalidomide 57 recurrent DVT 57 specific alkaline phosphatase 57 perioperative morbidity 57 -#.# log# 57 cerebral oxygenation 57 Randomized Evaluation 57 distant metastasis 57 SYMBICORT pMDI 57 elotuzumab 57 Subgroup analysis 57 High Dose quadruples 57 pharmacokinetic pharmacodynamic 57 bronchodilatory 57 persistency mortality 57 Ceplene/IL-2 57 hemodynamic parameters 57 anthracycline induced 57 thromboembolic events 57 intraobserver 57 CorVue ™ 57 tolerability pharmacokinetics 57 STELARA ® 57 intracerebral haemorrhage 57 pharmacodynamics 57 blood glucose concentrations 57 prolonged QT interval 57 dual endothelin receptor antagonist 57 guanfacine extended release 56 subcutaneous dose 56 acute GVHD 56 divalproex sodium 56 liver decompensation 56 pharmacokinetic PK study 56 triiodothyronine 56 postoperative chemotherapy 56 oxymorphone ER